Company profile: Synergia Medical
1.1 - Company Overview
Company description
- Provider of optoelectronic neurostimulation devices and platforms, including NAO.VNS for drug-resistant epilepsy via Vagus Nerve Stimulation, and technologies such as non-metallic encapsulation, fast wireless charging, custom optical leads, and miniaturized photovoltaic cells to advance therapies for chronic pain, Parkinsonβs disease, epilepsy, sleep apnea, and depression.
Products and services
- Neural Stimulation Technological Platform: A platform-based framework that advances neural stimulation therapies targeting chronic pain, Parkinsonβs disease, epilepsy, sleep apnea, and depression across multiple neurological indications
- NAO.VNS: A quartz optoelectronic neurostimulator engineered to deliver Vagus Nerve Stimulation (VNS) specifically for treating drug-resistant epilepsy
- Non-metallic Encapsulation: An MRI-compatible packaging approach that encapsulates neurostimulators without metal, enhancing patient safety and imaging compatibility during MRI procedures
Key contacts
π
π
Financial details
π
1.2 - Competitors and similar companies to Synergia Medical
Javelin Pharmaceuticals
HQ: United States
Website
- Description: Provider of specialty pharmaceutical research, development, and commercialization of products for the pain management market primarily in the United States and Europe, focusing on treatments for various pain disorders ranging from acute and episodic moderate-to-severe pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Javelin Pharmaceuticals company profile β
Coaxia
HQ: United States
Website
- Description: Provider of medical device research and development focused on therapy and treatment solutions for cerebral ischemia; based in Minneapolis, MN.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Coaxia company profile β
Seaport Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical solutions, including the Glyph platform, a proprietary lymphatic-targeting technology enabling and enhancing oral drug administration by bypassing first-pass metabolism and reducing hepatotoxicity, and SPT-300, an oral prodrug of allopregnanolone for treating mood and anxiety disorders, including anxious depression.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Seaport Therapeutics company profile β
Cerebral Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage therapies and technology for direct-to-brain drug delivery, including CT-010, a proprietary valproic acid formulation delivered via an implanted, refillable catheter and pump for refractory epilepsy; the ICVRx platform enabling intracerebroventricular delivery of drugs, biologics, and oligonucleotide therapies; and clinical trials evaluating therapies for neurological diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Cerebral Therapeutics company profile β
Minerva Neurosciences
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical product candidates for central nervous system diseases, including roluperidone (MIN-101) for negative symptoms of schizophrenia targeting serotonin, sigma, and alpha-adrenergic receptors, and MIN-301, a recombinant neuregulin-1Ξ²1 in preclinical development for Parkinsonβs disease aimed at restoring brain tissue damage and improving motor function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: βββββ
- Total funding raised: $βββm
- Backers: ββββββββββ
- Acquisitions: ββ
View full Minerva Neurosciences company profile β
π
2.M&A buyers
2.1 Potential strategic acquirers in the sector
π
π
π
π
View all strategic buyers with complete profiles
Start Free Trial β
2.2 - Strategic buyer groups for Synergia Medical
π
Buyer group 1: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 2: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π
Buyer group 3: ββββββββ ββββββββ
ββ companies
Description: ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ ββββββββ
Key Products: ββββββββ, ββββββββ, ββββββββ, ββββββββ
π
View all companies in this group
Request Free Trial Now β
π Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial β
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Synergia Medical
2.2 - Growth funds investing in similar companies to Synergia Medical
π
View all growth equity funds with complete profiles
Start Free Trial β
4 - Top valuation comps for Synergia Medical
4.2 - Public trading comparable groups for Synergia Medical
π Unlock all public trading comparable groups with complete valuation data
Start Free Trial β